Yusuke Nishikawa

Cultural Nuances when Conducting Business in Japan I held a keynote: Learn how to build successful business relationships in Japan's biopharma sector. My talk at BioStock Global Forum 2024 can be highly useful! Watch the keynote on YouTube, or enjoy the transcript. #CulturalInsights #Biopharma #Japan #BusinessRelationships #Healthcare #BioStockForum #StrategicGrowth https://lnkd.in/eRDxSqX5

1

📢【Taiwan Biotech Shines at the 2024 US BIO】📢 The North American Biotechnology Exhibition (US BIO), held in San Diego, California, USA, is a premier platform for showcasing the latest biotech innovations and promoting international collaboration! 🎉 Our exhibits included: 🔬 Five major technology platforms 💡 Seven innovative technologies 🏢 Taiwan Pavilion 🗣️ Taiwan Biotech Forum Additionally, the delegation visited several key institutions in Phoenix, including: 🧠 Barrow Neurological Institute 🧬 Translational Genomics Research Institute 🏥 Mayo Clinic These exchanges enabled Taiwan to discuss trends in brain and neurological disease treatment, genomics research, precision medicine, next-generation biopharmaceuticals, digital healthcare, and more with top US biotech institutions, creating endless business opportunities! 🤝 A total of 21 Taiwanese companies and academic institutions actively participated. The Taiwan Pavilion attracted significant international attention, leaving a lasting impression on the global stage. We look forward to more opportunities to promote Taiwan-US biotech exchanges and cooperation, creating a brighter future together! 🚀🌐 #2024USBIO #TaiwanBiotech #PrecisionMedicine #InternationalCooperation #DCB #BiotechInnovation #TaiwanUSExchange

8

A great talk with Nucleate Taiwan! We talk about the need to age de-escalate bio-tech entrepreneurship. I learned that there is such a hunger among biotech undergraduate or graduate students to learn more about the business side of biotech. Students from all over Taiwan literally take high speed trains to be part of Nucleate’s activities during weekday evening. What can we do to offer more of these opportunities?

31

3件のコメント

Discover how strategic differences between Japanese and foreign pharmaceutical companies impact market success in Japan. Dr. Uyama's latest research explores a decade of drug development, revealing critical insights into overcoming the "drug lag" by embracing global partnerships and multi-regional clinical trials. Dive into the details on our blog! #Pharmaceuticals　#DrugDevelopment　#JapanHealthcare　#PharmaStrategy

10

1件のコメント

As an #ExecutiveRecruiter specializing in BioPharma in Japan, I've gained unique insights into the sector's remarkable transformation. From 2009 to 2023, global BioPharma revenue has surged from $664B USD to over $1T USD, driven by contributions from a diverse array of innovative companies. Key observations:           ■ Global leaders:                   □ Companies like J&J, Pfizer, MSD / Merck, AbbVie, Novartis, Roche, Sanofi, AstraZeneca, GSK, and Bristol Myers Squibb continue to drive significant advancements in healthcare worldwide.           ■ Japanese influence:                   □ Five major Japanese firms - Takeda, Astellas, Daiichi Sankyo, Otsuka, and Chugai – have secured positions among the global leaders, showcasing Japan's important role in the industry.           ■ Emerging innovators:                   □ Companies like Regeneron, Biogen, and Gilead Sciences are making substantial impacts in specialized treatments and rare diseases.           ■ Diversified healthcare:                   □ The presence of CSL, IQVIA, and LabCorp in the rankings highlights the importance of diagnostics, clinical research, and plasma-derived therapies.           ■ Rising stars:                   □ Japan's BioPharma landscape is evolving rapidly, with PeptiDream and Kyowa Kirin pioneering novel therapeutics, while Sumitomo Pharma expands its global footprint.                   □ Eisai is gaining renewed attention for its Alzheimer's research, and Ono Pharmaceutical continues to build on its immuno-oncology success. Japan's position as the world's third-largest pharmaceutical market, valued at ¥10.9 trillion (~$75B USD) in 2022, makes it a key player in global BioPharma strategies. Looking ahead, we're seeing increased competition for professionals skilled in #AI, #datascience, and personalized medicine across all these companies, both in Japan and globally. Japan's PMDA is implementing a new digital transformation strategy, which could really streamline drug approval processes and accelerate innovation. In recent conversations with BioPharma executives, I've observed a growing emphasis on building teams with diverse skill sets, particularly in data science and digital health, reflecting the move towards more personalized and technology-driven healthcare solutions. I'm committed to helping both multinational and Japanese companies build leadership teams that can drive the next wave of BioPharma breakthroughs. Happy to hear your thoughts! #ExecutiveRecruitment #GlobalBioPharma #JapanesePharma #HealthcareInnovation Total revenue reported may include revenue from a company’s medical or diagnostics divisions. Content has been sourced from public data and intended for educational purposes only. Data visualization by Reza Zahiri, PhD, MBA (Original video content used with permission - https://t.ly/bwBaF) Music: We have a Dream – Joey Richmond Sources: MacroTrends, Statista, Individual company filings, others

1,466

31件のコメント

More data on the structural changes impacting labor markets in Japan. As labor liquidity increases, so does the necessity for hiring business capabilities by companies to effectively compete for and secure the talent they need to win. After spending the last week talking with industry leaders in global HRTech, I’m convinced that Japan is in the cusp of dynamic changes over the next several years. Not only are institutional investors plowing into the space through PE deals, but global leading technology and service providers now have their eyes on Japan and broader Asia for growth and I can only feel that this will be a net positive on organizational competitiveness and opportunity for talent at the same time. Feeling very exciting about the years to come and will have more updates from ZooKeep soon about things we are doing to lift the ecosystem in Asia. #growth #peoplematter #opportunity

20

1件のコメント

During my last trip to Shanghai, I had the opportunity to sit down with reporters of HealthInsight, a leading healthcare media company in China. 🇨🇳 We spoke about many things, including why I started VentureBlick and our mission of taking healthcare innovation global. Here are some translated excerpts of my views from the article. 🌍 Chinese companies are generally not prepared to go overseas – in terms of mentality, talent, or ability. While the desire to go global, Chinese healthcare companies still lack global awareness and strategies to penetrate overseas markets. In the 16 years that Chris Lee led the China business for Bayer Healthcare and Medtronic, he witnessed tremendous changes in the Chinese healthcare industry and the innovative breakthroughs made by many healthcare companies, but the road to going global has not been smooth. Many Chinese companies still dare not face the competition of international giants in developed countries. They prefer to explore developing countries in Southeast Asia, the Middle East, and Africa when going overseas, taking the route of affordability. But one should be more strategic in choosing the first overseas market. The first market could very well affect entry into subsequent and bigger market such as Europe and the United States. 🌍 For more insights, you might like to read the full Chinese article on WeChat: https://lnkd.in/gQHd9P48 If you’re on WeChat, follow VentureBlick! https://lnkd.in/gb4Wtsmi #goglobal #China #healthcare #innovations #featured

70

10件のコメント

　We are thrilled to share that Surg storage has commenced a partnership with the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) to advance surgical support AI through our high-quality surgical video database, "S-access Japan". 📅 In January 2024, we solidified our data utilization agreement, and by March, we successfully delivered our first set of data to SAGES. This collaboration aims to enhance the quality of surgical techniques globally and drive the evolution of AI in medicine. 👩‍⚕️ The data, accumulated from over 100 collaborating hospitals across Japan, will be instrumental in SAGES' upcoming surgical support AI competitions. Spearheaded by Dr. Ozanan Meireles of Duke University, these efforts are set to revolutionize how surgeries are supported technologically. 🌍 This initiative not only showcases our commitment to "visualizing healthcare to deliver optimum information" but also positions Surg storage as a pivotal contributor to global medical technology advancements. Our CEO, Mr.Akihiro Hirao, expressed his pride in this significant achievement, stating, "Our collaboration with SAGES enables Japanese surgical data to contribute to the global evolution of surgical support, marking a proud moment for our team." 🔍 As we continue to collaborate with surgeons and medical professionals worldwide, we aim to build a foundation for safer and more effective AI-driven surgical solutions. Stay tuned as we forge ahead in our mission to transform surgical practices globally. https://lnkd.in/gerfygw7 #SurgStorage #SAGES #MedicalAI #SurgicalInnovation #GlobalHealthcare

14